Dyne Therapeutics, Inc.

By person

29 insiders · 477 transactions

11.4×

John G. Cox holds 11.4 times base salary in stock. $8.26M of shares against $721.00K in salary for 2025.

Salary from the company's own proxy. The shares are what John G. Cox last reported holding, valued at $18.88, the price Common Stock was last bought or sold at on the open market here, on 8 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Rhodes Jason P

Director

$10.00M (1)

$173.35M (114) scheduled

−$163.35M

428,946

0.2297%

$8.10M

—

Kersten Dirk

Director

$30.00M (2)

$136.30M (88) scheduled

−$106.30M

3,586,796

1.92%

$67.72M

—

Atlas Venture Fund XI, L.P. entity

10% owner

—

$42.83M (29) scheduled

−$42.83M

6,562,578

3.51%

$123.90M

+321.5%

Brumm Joshua T

CEO & President

—

$26.68M (31) scheduled

−$26.68M

537,998

0.2881%

$10.16M

—

VV Manager II, LLC entity

10% owner

$15.49M (2)

—

+$15.49M

79,921

0.0428%

$1.51M

—

Logos Global Management LP entity

10% owner

$13.30M (1)

—

+$13.30M

1,504,392

0.8056%

$28.40M

—

RA CAPITAL MANAGEMENT, L.P. entity

10% owner

$12.54M (1)

—

+$12.54M

2,805,045

1.50%

$52.96M

—

Atlas Venture Opportunity Fund II, L.P. entity

10% owner

$10.00M (1)

—

+$10.00M

934,581

0.5005%

$17.64M

—

Scalzo Richard William

SVP, Head of Finance & Admin.

—

$8.71M (40) scheduled

−$8.71M

122,330

0.0655%

$2.31M

—

HIGH SUSANNA GATTI

Chief Operating Officer

—

$7.06M (28) scheduled

−$7.06M

131,636

0.0705%

$2.49M

—

McNeill Jonathan

Chief Business Officer

—

$5.63M (34) scheduled

−$5.63M

132,106

0.0707%

$2.49M

+563.9%

Beskrovnaya Oxana

Chief Scientific Officer

—

$3.50M (30) scheduled

−$3.50M

195,840

0.1049%

$3.70M

—

Atlas Venture Opportunity Fund I, L.P. entity

10% owner

—

$1.40M (2) scheduled

−$1.40M

2,306,079

1.23%

$43.54M

−2.0%

Cox John

CEO & President

$1.97M (9)

$581.33K (9) scheduled

+$1.39M

437,507

0.2343%

$8.26M

+725.5%

Farwell Wildon

Chief Medical Officer

—

$955.49K (21) scheduled

−$955.49K

143,222

0.0767%

$2.70M

—

Incerti Carlo

Director

—

$474.05K (1) scheduled

−$474.05K

0.0000%

$0.00

—

Kerr Douglas

Chief Medical Officer

—

$325.76K (11) scheduled

−$325.76K

162,564

0.0871%

$3.07M

—

Posner Brian S

Director

$274.84K (7)

—

+$274.84K

24,500

0.0131%

$462.56K

+188.2%

Lucera Erick

Chief Financial Officer

—

$228.68K (4) scheduled

−$228.68K

119,766

0.0641%

$2.26M

—

Friedl-Naderer Johanna

Chief Commercial Officer

—

$60.86K (11) scheduled

−$60.86K

152,897

0.0819%

$2.89M

—

Forbion Capital Fund IV Cooperatief U.A. entity

10% owner

—

6,131,079

3.28%

$115.75M

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

10% owner

—

1,608,785

0.8615%

$30.37M

—

CureDuchenne Ventures, LLC entity

10% owner

—

602,972

0.3229%

$11.38M

—

Subramanian Romesh

Chief Scientific Officer

—

566,249

0.3032%

$10.69M

+7.9%

Stehman-Breen Catherine

Director

—

115,713

0.0620%

$2.18M

+10.2%

HURWITZ EDWARD

Director

—

91,081

0.0488%

$1.72M

—

MPM BIOVENTURES 2018, L.P.

10% owner

—

91,081

0.0488%

$1.72M

—

Klein Lawrence Otto

Director

—

10,725

0.0057%

$202.49K

—

Lubner David Charles

Director

—

0.0000%

$0.00

—

By person

Individual transactions

What was left out